2 results
Approved WMORecruiting
To determine the microbiological and clinical cure rate after 14 days.
Approved WMOWill not start
The purpose of this study is to evaluate the possible risks and efficacy (improvement of disease) with an experimental oral study drug named eliglustat in pediatric patients from 2 to 18 years with Gaucher disease.